307 related articles for article (PubMed ID: 34123863)
1. Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis.
Zang J; Ye K; Fei Y; Zhang R; Chen H; Zhuang G
Front Oncol; 2021; 11():696716. PubMed ID: 34123863
[TBL] [Abstract][Full Text] [Related]
2. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
Yang Z; Xu Y; Bi Y; Zhang N; Wang H; Xing T; Bai S; Shen Z; Naz F; Zhang Z; Yin L; Shi M; Wang L; Wang L; Wang S; Xu L; Su X; Wu S; Yu C
J Clin Transl Res; 2021 Aug; 7(4):485-500. PubMed ID: 34541363
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
4. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Cheng W; Fu D; Xu F; Zhang Z
Oncogenesis; 2018 Jan; 7(1):2. PubMed ID: 29358573
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology.
Choi HW; Naskar M; Seo HK; Lee HW
Biomedicines; 2021 Oct; 9(11):. PubMed ID: 34829729
[TBL] [Abstract][Full Text] [Related]
6. Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.
Huang CP; Wu CC; Shyr CR
Cancer Immunol Immunother; 2021 May; 70(5):1419-1433. PubMed ID: 33156394
[TBL] [Abstract][Full Text] [Related]
7. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
8. Mass cytometry reveals immune atlas of urothelial carcinoma.
Zhang Q; Zhang W; Lin T; Lu W; He X; Ding Y; Chen W; Diao W; Ding M; Shen P; Guo H
BMC Cancer; 2022 Jun; 22(1):677. PubMed ID: 35725444
[TBL] [Abstract][Full Text] [Related]
9. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
10. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
Peng M
Front Immunol; 2022; 13():970885. PubMed ID: 36003383
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
12. Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer.
Li T; Liu T; Zhao Z; Pan Y; Xu X; Zhang Y; Zhan S; Zhou S; Zhu W; Guo H; Yang R
Front Immunol; 2022; 13():911325. PubMed ID: 36131933
[TBL] [Abstract][Full Text] [Related]
13. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
14. Comparison of molecular profiles of upper tract urothelial carcinoma
Tomiyama E; Fujita K; Hashimoto M; Adomi S; Kawashima A; Minami T; Yoshimura K; Uemura H; Nonomura N
Transl Androl Urol; 2022 Dec; 11(12):1747-1761. PubMed ID: 36632153
[TBL] [Abstract][Full Text] [Related]
15. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue "Seminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma".
Chu C; Pietzak E
Urol Oncol; 2023 Oct; 41(10):398-409. PubMed ID: 35811207
[TBL] [Abstract][Full Text] [Related]
16. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
17. The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer.
Huang CP; Chen CC; Shyr CR
Cytotherapy; 2017 Oct; 19(10):1233-1245. PubMed ID: 28818454
[TBL] [Abstract][Full Text] [Related]
18. Strategies for Overcoming Immune Evasion in Bladder Cancer.
Shin J; Park JW; Kim SY; Lee JH; Choi WS; Kim HS
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542078
[TBL] [Abstract][Full Text] [Related]
19. Single-cell atlases link macrophages and CD8
Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
[No Abstract] [Full Text] [Related]
20. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
